Supplementary material for Pøhl et al., Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer, Acta Oncologica, 2015; doi: 10.3109/0284186X.2015.1049291

Supplementary Table 1 Patient demographics in the “Original” Norwegian Cohort and the “Modified” Cohort and relation with survival.

Patient Characteristics	Cancer-specific Survival			P	Cancer-specific Survival			P
	Original Norwegian Cohort (n = 335)	Median Survival months	5-Year Survival %		Modified Norwegian cohort (n = 276)	Median Survival months	5-Year Survival %	
Age (mean) years [range]	65.5 [27–85]			0.98	65.8 [39–85]			0.99
Gender								
Female	82 (25%)	190	63		68 (25%)	190	66	
Male	253 (75%)	83	56	0.2	208 (75%)	84	56	0.13
Histology								
Adenocarcinoma	113 (34%)	54	45		88 (32%)	51	43	
Squamous cell c	191 (57%)	NR	66		165 (60%)	NR	67	
Large cell carc	31 (9%)	98	56	0.03	23 (8%)	98	58	0.02
ECOG perf. status								
0	197 (59%)	NR	63		157 (57%)	NR	63	
1–2	138 (41%)			0.02	119 (43%)	64	52	0.05
TNM stage*								
I	157 (47%)	NR	72		120 (43%)	190	73	
II/IIIA	178 (53%)	42	45	<0.0001	156 (57%)	47	47	<0.0001
T-Stage								
1	85 (25%)	190	75		64 (23%)	190	74	
2	188 (56%)	84	57		157 (57%)	NR	60	
3/4	62 (19%)	25	37	0.0001	55 (20%)	23	34	0.0003
N-Stage								
0	232 (69%)	NR	67		188 (68%)	NR	67	
1–2	103 (31%)	27	36	<0.0001	88 (32%)	29	40	<0.0001
Vascular infiltration								
No	284 (85%)	190	62		236 (86%)	190	61	
Yes	51 (15%)	27	33	0.0005	40 (14%)	35	38	0.006
Differentiation								
Poor	138 (41%)	47	47		115 (42%)	47	49	
Moderate/Well	197 (59%)	NR	66	<0.0001	161 (58%)	NR	66	0.0002
Surg. procedure								
Lobectomy/wedge	243 (73%)	190	62		190 (69%)	190	62	
Pneumonectomy	92 (27%)	37	47	0.008	86 (31%)	52	49	0.02

Abbreviations: ECOG, Eastern Cooperative Oncology Group; n.s. non significant values were excluded in the multiple Cox proportional-hazard regression analysis; HR, Hazard Ratio; 95%CI, 95% Confidence interval; vs. versus. n.a. not available. NR indicates not reached.

Supplementary Figure 1. (A-D): immunohistochemical analysis of keratin 34β12 and K7 expression in non-small cell lung cancer (NSCLC). For K7, cores with tumor cell content of $\geq 10\%$ staining were considered positive and tumors with $\geq 1\%$ staining of the tumor cells for 34βE12 were considered positive. (S1A1-3) 34β12 expression in lymph node negative (N0) tumors in the Danish, Norwegian and combined cohort. (S1B1-3) 34β12 expression in lymph node positive (N1-N2) tumors in the Danish, Norwegian and combined cohort. (S1C1-3) K7 expression in lymph node negative (N0) tumors in the Danish, Norwegian and combined cohort. (S1D1-3) K7 expression in lymph node positive (N1-N2) tumors in the Danish, Norwegian and combined cohort.

Supplementary Figure 1. (Continued)

Supplementary Figure 2. Cancer-specific survival in 11 (3%) tumors in the Norwegian cohort that neither expressed 34βE12 nor K7. The sample size was too small for meaningful comparison. Most of those tumors were squamous cell carcinomas (n = 6) or NSCLC (n = 3) (n = 9; 82%) with CSS comparable to the tumors expressing 34βE12+/K7-.

Supplementary Figure 3. (A–B) Cancer-specific survival in adenocarcinomas and squamous cell carcinomas related to keratin expression patterns using log-rank test. (A) Kaplan-Meier cancer-specific survival curves in adenocarcinomas according to keratin expression patterns (34βE12/K7) in the combined Danish and Norwegian cohort. (B) Kaplan-Meier cancer-specific survival curves in squamous cell carcinomas according to keratin expression patterns (34βE12/K7) in the combined Danish and Norwegian cohort.